semaj83/ctmatch_classification huggingface dataset:
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Rhinitis Seasonal Patients with seasonal allergic rhinitis (SAR): Patients with a history of SAR symptoms during the season when cedar pollen levels are increased for at least 2-years  At the start of the placebo lead-in period Patients who are negative for IgE Antibody test Expected nasal congestion score is less than 2 The last 3 days of the lead-in period Nasal congestion scores are 2 or more and not all 4 Patients with all nasal symptoms (sneezing, rhinorrhea, and nasal congestion). A total score for nasal symptoms (sneezing, rhinorrhea, and nasal congestion) and eye symptom is less than 6 Patients with 2 or more nasal symptoms (sneezing and rhinorrhea) and eye symptoms score is 4 The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Healthy Asthma Male healthy subjects and male asthma patients aged 18 to 45 years (inclusive) Have a body mass index (BMI) between 18 and 30 kg/m2 (inclusive and rounding allowed) and weight between 50 and 100 kg (inclusive) Be able to inhale from the SPIRA nebuliser and I-neb® according to the provided instructions Asthma patients should fulfil the following Pre-bronchodilator forced expiratory volume at 1 second (FEV1) ≥70% of predicted normal value Asthma diagnosis according to GINA guidelines with a history of episodic wheeze and shortness of breath  History of any clinically significant disease or disorder Any clinically relevant abnormal findings Current smokers Asthma patients: Worsening of asthma or respiratory infection within 6 weeks before screening Asthma patients: Use of inhaled, nasal, oral, rectal or parenteral corticosteroids within 30 days before first administration of investigational product and during the study
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Asthma Subjects with asthma as determined by ICD-9 codes and asthma drug use at least 12 years of age discharged from an initial Emergency Department visit within 12 months  Subjects with COPD or treatment for COPD
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Driving Distress Secondary to Trauma During Deployment Driving-related distress secondary to conditions of OEF/OIF deployment 2. Possesses valid driver's license 3. Owns vehicle registered in his/her name 4. Vehicle currently insured in his/her name 5. Drives regularly (e.g. to regularly scheduled activities such as work or school) 6. Drives to all driving rehabilitation appointments  Any moving violations since discharge from the military 2. Any central nervous system injury or disease 3. Psychotic disorder and/or any psychotic signs or symptoms 4. Current alcohol or substance abuse/dependence (required answer: "yes" or "no", only) 5. Severe Post-traumatic Stress Disorder (as indicated by a PTSD Checklist (PCL) score greater than 60) 6. Severe Depression(as indicated by a Beck Depression Inventory-II score greater than 28) 7. Amputation or restricted mobility of any limb
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Obesity Morbid Obesity Venous Thromboembolism Atrial Fibrillation Angina Chest Pain Patients with body mass index greater than or equal to 30 Patients admitted to Nazareth Hospital inpatient units Weight-based intravenous heparin, with a diagnosis of atrial fibrillation, suspected or confirmed deep vein thrombosis or pulmonary embolism, unstable angina or Non ST elevation myocardial infarction with hemodynamic stability, or peripheral vascular disease, ordered at the time of admission/transfer or during the patient stay in the Intensive Care unit or Progressive Care unit Prior permission from the patient's attending physician Permission from the physician who ordered the intravenous weight-based heparin (if different from the attending) Signed consent form by the patient  Patients with stroke, TIA, or ST elevation myocardial infarction Patients who have hemodynamic or cardiopulmonary instability at the time of intravenous heparin order Patients with thrombophilia Patients who are pregnant or may be pregnant Those patients who have been on any oral anticoagulants (Warfarin, rivaroxaban, dabigatran or apixaban), treatment dose of other anticoagulants or intravenous thrombolytics in previous 7 days Patients who have a PTT greater than 37 seconds History of heparin-induced thrombocytopenia or known allergy to heparin Deviation from the Weight-based heparin protocol ordered by a physician at the time intravenous heparin was written (i.e. no bolus dose ordered, different target therapeutic aPTT range, different bolus dose per kg, etc.) Informed consent either refused or not obtained Objection from a physician caring for the patient
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Orthostatic Hypotension The presence of orthostatic hypotension (fall in systolic BP greater than or equal to 30 mm Hg) is required for this study; 2. Autonomic testing and clinical evaluation demonstrates OH to be of neurogenic etiology
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 30.0-80.0,  COPD Asthma Male or female outpatients aged 40-80 years inclusive An established clinical history of COPD as defined by the GOLD guidelines COPD patients with a baseline (pre-bronchodilator) FEV1 40-80% of predicted normal value; post-bronchodilator FEV1/FVC ratio ≤ 70% predicted COPD patients with a smoking history (current or ex-smoker) of ≥10 pack years or those who have exposure to occupational dust and chemicals An established clinical history of asthma defined by the GINA recommendations Subjects with out hypoxemia (all subjects must have an O2 saturation ≥88% on room air). Control (healthy) subjects with baseline FEV1 >80% of predicted normal value A female is eligible to participate this study if she is of non-childbearing potential, or childbearing potential has a negative pregnancy test Patients who did not use inhaled and oral corticosteroids 6 weeks and/or long acting bronchodilators 4 weeks before study  There is a current respiratory disorder other than COPD and asthma (e.g. lung cancer, sarcoidosis, active tuberculosis etc.) Subjects who have had a COPD and asthma exacerbation or respiratory infection in the 4 weeks before Visit 1 Subjects with a chest X-ray indicating diagnosis other than COPD or asthma that might interfere with the study Subjects who are unable to stop treatment with inhaled, and oral corticosteroids 6 weeks and/or long acting bronchodilators 4 weeks before study Subjects receiving treatment with cromolyn sodium or nedocromil, oral beta2 - agonists, long acting anticholinergic, leucotriene modifiers Subjects who have had lung surgery Subjects with bleeding diathesis Subjects receiving treatment with long-term oxygen therapy Subjects with serious, uncontrolled diseases those are uncontrolled on permitted therapy
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 2.0-80.0,  Chronic Cough Age 2-80 years Patients with significant chronic cough Patients in hemodynamic stability. Patient is not in respiratory distress Subject or subject's parents/guardians is able to comprehend and give informed consent for participation in the study  Contraindication to the use of the PulmoTrack™ or performing ARM (Acoustic Respiratory Monitoring) Hemodynamic instability and/or SOB Concurrent additional major illness Concurrent participation in any other study Physician objection
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Bronchial Asthma subjects aged between 18 and 65，without acute upper respiratory tract infection for the past 2 weeks had a normal chest radiographic result had a baseline spirometry with the forced expiratory volume in one second (FEV1) of not less than 60% predicted had withheld leukotriene receptor antagonists (LTRA) for over 5 days oral glucocorticosteroid or anti-histamine for 3 days oral xanthenes or long-acting bronchodilators for 2 days inhaled corticosteroid or long-acting bronchodilator for a day as well as short-acting bronchodilator for 4 hours prior to the measurement  subjects had a fall of no less than 15% in FEV1 after repetitive forced respiration or a fall of no less than 20% in FEV1 after the inhalation of ethanol diluent control had a past confirmed history of respiratory disease other than bronchial asthma (COPD, bronchiectasis, pulmonary thromboembolism, etc.) or other severe systemic disease（myocardial infarction, malignant tumor, etc.） had a poor cooperation to the test or limited understandings, were immunocompromised, or had participated other clinical trials for the past 3 months
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 12.0-65.0,  Asthma One or more medical claims with a diagnosis (primary or secondary) of asthma (ICD-9-CM 493.XX) during study period One or more outpatient pharmacy claims during the study for one or more of the following "study medications" Fluticasone propionate/salmeterol xinafoate 250 mcg/50 mcg or 100mcg/50mcg combinations Fluticasone propionate 110 mcg or 220 mcg One or more asthma exacerbations (asthma-related hospitalization or emergency department visit, oral corticosteriod prescription drug claim, or a combination of any of the above events) during the 12 months prior to the index date ("pre-index period") or Five or more prescriptions for a short-acting beta agonist during the pre-index period  Patients with more than one of the study medications during the 3-month period beginning with the index date One or more prescriptions within three months of index date (pre or post) for an ICS or LABA other than the study medications One or more prescriptions within three months of post index date for Any asthma maintenance medication Any medical claims during study period with a diagnosis of: Chronic obstructive pulmonary disease (COPD) (ICD-9-CM 491, 492, or 496); or Respiratory tract cancer (ICD-9-CM 160-164, or 231)
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 12.0-50.0,  Asthma Outpatient male or female 12 to 50 years of age Females of child-bearing potential must be willing to use birth control or commit to abstinence during the study Diagnosis of persistent asthma for at least 6 months Best pre-bronchodilator FEV1 of at least 70% Current use of a low to moderate-dose inhaled corticosteroid Ability to withhold albuterol 6 hours prior to visits Physically able to perform exercise testing on a treadmill when albuterol has been withheld  Intermittent asthma, seasonal asthma, or exercise-induced asthma only Symptomatic allergic rhinitis and/or thrush Abnormal, clinically significant electrocardigraph Respiratory infection within 4 weeks of first visit leading to asthma medication change or could affect subjects's asthma status or participation Asthma exacerbation within 12 weeks of first visit Respiratory diseases or other concurrent disease that would put subject at risk or confound results interpretation Investigational medicines within 30 days of first visit or less than five half-lives of medication in prior study Allergy to study drugs or study drug excipients Concomitant medications that could interact with study medications or affect the course of asthma Tobacco use within last year and/or a 10 pack-years history